Informace o publikaci

Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade

Autoři

LAKOMÝ Radek KAZDA Tomáš SELINGEROVÁ Iveta POPRACH Alexandr POSPÍŠIL Petr BELANOVÁ Renata FADRUS Pavel VYBÍHAL Václav SMRČKA Martin JANČÁLEK Radim HYNKOVÁ Ludmila MÚČKOVÁ Katarína HENDRYCH Michal ŠÁNA Jiří SLABÝ Ondřej ŠLAMPA Pavel

Rok publikování 2020
Druh Článek v odborném periodiku
Časopis / Zdroj Frontiers in Oncology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.frontiersin.org/articles/10.3389/fonc.2020.00840/full
Doi http://dx.doi.org/10.3389/fonc.2020.00840
Klíčová slova glioblastoma; chemotherapy; radiotherapy; rapid early progression; overall survival; real-world evidence
Popis The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our cancer center was compared with an already published historical control of patients treated in 1/2003-12/2009. A total of new 155 patients was analyzed, median age 60.9 years, 61% men, 58 patients (37%) underwent gross total tumor resection. Stupp's regimen was indicated in 90 patients (58%), 65 patients (42%) underwent radiotherapy alone. Median progression-free survival in Stupp's regimen cohort was 6.7 months, median OS 16.0 months, and 2-year OS 30.7%. OS was longer if patients were able to finish at least three cycles of adjuvant chemotherapy (median 23.3 months and 43.9% of patients lived at 2 years after surgery). Rapid early progression prior to radiotherapy was a negative prognostic factor with HR 1.87 (p= 0.007). The interval between surgery and the start of radiotherapy (median 6.7 weeks) was not prognostically significant (p= 0.825). The median OS in the current cohort was about 2 months longer than in the historical control group treated 10 years ago (16 vs. 13.8 months) using the same Stupp's regimen. Taking into account differences in patient's characteristics between current and historical cohorts, age, extent of resection, and ECOG patient performance status adjusted HR (Stupp's regimen vs. RT alone) for OS was determined as 0.45 (p= 0.002).